# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0000000000-25-010384
**Filing Date:** 2025-9
**Character Count:** 3610
**Document Hash:** 244ca66af8141ee601601f98730cd094
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010384.hdr.sgml**: 20260625

**ACCESSION NUMBER**: 0000000000-25-010384

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250924

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290309

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-205145

## Text-Extract

```

                                                            September 24, 2025

James Rolke
Chief Executive Officer
Revelation Biosciences, Inc.
4660 La Jolla Village Drive, Suite 100
San Diego, CA 92122

       Re: Revelation Biosciences, Inc.
           Registration Statement on Form S-3
           Filed September 16, 2025
           File No. 333-290309
Dear James Rolke:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe this comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3
General

1.     We note that this Form S-3, among other things, constitutes a
post-effective
       amendment to prior registration statements on Form S-1 (File Nos.
333-268576, 333-
       276232 and 333-287423), but you appear to have omitted the disclosure
required by
       the form and Regulation S-K as it pertains to those offerings. Please
revise the
       registration statement to include all of the form and Regulation S-K
information that
       currently would be required in a prospectus relating to those offerings.
Refer to Rule
       429 under the Securities Act of 1933, as amended.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 September 24, 2025
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jimmy McNamara at 202-551-7349 or Alan Campbell at
202-551-4224
with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Joseph P. Galda

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._